3-D Matrix (7777) AI Stock Analysis

• Market Cap: ¥61.23B
• Dividend Yield: N/A
• Average Volume (3M): 4.78M
• Price to Earnings (P/E): 20.6
• Beta (1Y): 1.59
• Revenue Growth: 40.50%
• EPS Growth: 91.59%
• Country: JP
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 7.99
• Shares Outstanding: 124,965,080
• 10 Day Avg. Volume: 2,399,770
• 30 Day Avg. Volume: 4,782,760
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.64
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -7.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: ¥418.00 ▲(20.11% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held back primarily by weak financial performance (persistent losses, negative operating cash flow, and high leverage). Technicals provide partial support with price above key longer-term moving averages, while valuation appears reasonable at a mid-range P/E but lacks dividend yield support.

Positive Factors

Proprietary peptide platform

3-D Matrix’s proprietary self-assembling peptide platform is a durable competitive asset that supports multiple medical applications (wound care, surgical aids, tissue regeneration). A platform technology creates high switching costs, enables licensing, and supports long-term product pipeline and margin expansion.

Negative Factors

High financial leverage

A debt-to-equity of 1.33 signals material reliance on debt financing, raising interest and refinancing risk. High leverage constrains strategic flexibility for R&D and commercialization, increases vulnerability to revenue shortfalls, and can force suboptimal capital allocation during cyclic or regulatory stress.

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was ...

Read more

3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was ...

How the Company Makes Money

3-D Matrix generates revenue primarily by developing and commercializing its peptide-based biomaterials for the healthcare industry. The company licenses its technology to partners, sells its products directly, and collaborates with medical instit...

Read more

3-D Matrix generates revenue primarily by developing and commercializing its peptide-based biomaterials for the healthcare industry. The company licenses its technology to partners, sells its products directly, and collaborates with medical instit...

3-D Matrix Financial Statement Overview

Breakdown	TTM	Apr 2025	Apr 2024	Apr 2023	Apr 2022	Apr 2021
Income Statement
Total Revenue	7.64B	6.93B	4.59B	2.31B	1.51B	1.02B
Gross Profit	5.05B	4.42B	3.09B	1.29B	661.01M	304.91M
EBITDA	-725.87M	-2.40B	59.13M	715.00M	843.00M	638.00M
Net Income	-948.45M	-2.50B	-255.50M	-2.45B	-1.89B	-2.01B
Balance Sheet
Total Assets	6.37B	6.51B	5.89B	5.83B	5.61B	3.51B
Cash, Cash Equivalents and Short-Term Investments	1.49B	1.58B	1.36B	1.17B	2.85B	1.14B
Total Debt	2.33B	2.94B	4.17B	4.37B	3.67B	1.46B
Total Liabilities	3.68B	4.30B	5.53B	5.30B	4.15B	1.85B
Stockholders Equity	2.69B	2.22B	353.31M	524.77M	1.46B	1.66B
Cash Flow
Free Cash Flow	0.00	-1.73B	-1.90B	-4.60B	-2.92B	-3.28B
Operating Cash Flow	0.00	-1.71B	-1.90B	-4.59B	-2.90B	-3.25B
Investing Cash Flow	0.00	-33.30M	-29.76M	-81.50M	-79.86M	-160.32M
Financing Cash Flow	0.00	2.01B	2.06B	2.96B	4.66B	3.46B

3-D Matrix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 348.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Positive. The current price of 348 is below the 20-day moving average (MA) of 475.30, below the 50-day MA of 528.62, and below the 200-day MA of 348.28, indicating a neutral trend. The MACD of -23.33 indicates Negative momentum. The RSI at 49.22 is Neutral, neither overbought nor oversold. The STOCH value of 77.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7777.

3-D Matrix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	78 Outperform	¥19.50B	15.12	―	3.02%	-4.36%	-14.92%
4549	68 Neutral	¥113.08B	26.70	―	2.31%	4.36%	79.43%
7963	67 Neutral	¥9.44B	10.32	―	1.89%	9.47%	37.35%
6849	65 Neutral	¥258.59B	36.37	―	1.92%	4.31%	96.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6523	51 Neutral	¥138.76B	28.05	2.42%	3.73%	0.04%	―
7777	50 Neutral	¥61.23B	20.55	1.45%	―	40.50%	91.59%